Clinical Trial

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 22, 2024 (before its estimated December 10, 2024 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-09; most recent amendment 2024-10-20.
Trial Details
NCT Number NCT05726110
Lead Sponsor Shanxi Bethune Hospital
Collaborators: Antengene Corporation
Conditions Relapsed or Refractory Acute Myeloid Leukemia
Enrollment 50 participants
Start Date 2023-01-29
Primary Completion 2024-12-10 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-22